Jointly provided by
Support for this activity has been provided through an educational grant from Pfizer.
Release date: 9/6/2017
Expiration date: 9/6/2018
Estimated time to complete: 1.0 hour
Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and non–small cell lung cancer. Additionally, studies of CDK4/6 inhibition of cancers of the prostate, lung, skin, and central nervous system are currently under way.
In the format of an entertaining (but challenging!) interactive game, this edition of Scale, Bail or Fail presents and discusses the latest updates on CDK4/6 inhibition research and its clinical implications. This activity also features downloadable resources (including supplemental figures and tables).
Richard S. Finn, MD—Program Chair
Associate Professor of Medicine
University of California, Los Angeles
Los Angeles, California
Gary K. Schwartz, MD
Professor of Medicine
Chief, Division of Hematology and Oncology
Deputy Chief, Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York
Geoffrey I. Shapiro, MD, PhD
Director, Early Drug Development
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
This activity has been designed to meet the educational needs of medical oncologists, laboratory scientists and clinical investigators specializing in all aspects of cancer research, and other health care professionals interested in understanding the research advances in CDK4/6 inhibition.
Upon completion of this activity, participants should be able to:
- Explain the mechanism of action of CDK4/6 inhibitors
- Evaluate safety and efficacy data on the use of CDK4/6 inhibitors for solid tumors and their potential implications for clinical practice
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Richard S. Finn, MD, has disclosed the following relevant financial relationships:
Consultant: Bayer, Bristol-Myers Squibb, Novartis, Pfizer
Dr. Finn will discuss the off-label use of abemaciclib, palbociclib, and ribociclib.
Gary K. Schwartz, MD, has disclosed the following relevant financial relationships:
Advisory Board: Bionaut Labs, Champions Oncology, Human Longevity, Karyopharm
Consultant: BioMotiv, Darwin Health, Puretech Health
Other Relationships: AXIS Medical Education, Medscape/WedMD
Geoffrey I. Shapiro, MD, PhD, has disclosed the following relevant financial relationships:
Advisory Board: G1 Therapeutics, Lilly, Pfizer, Vertex
Grant Recipient: Pfizer
Dr. Shapiro will discuss the off-label use of abemaciclib, G1T28, palbociclib, and ribociclib.
University of Cincinnati
Deborah Cole, Program Coordinator, has disclosed no relevant financial relationships.
Rick E. Ricer, MD, Professor Emeritus, UC Physician Reviewer, has disclosed no relevant financial relationships.
Susan P. Tyler, MEd, CMP, CHCP, CME Director, has disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships.
Barbara Zosh, Director of Operations, has disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati, RedMedEd, and Pfizer do not recommend the use of any agent outside the labeled indications.
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, RedMedEd, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The University of Cincinnati is committed to resolving all conflict-of-interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the entire activity (achieving a passing grade by correctly answering at least nine questions) and program evaluation. Certificates can be printed immediately.
Accreditation support: contact the University of Cincinnati Continuing Medical Education Department at email@example.com or call (513) 558-7277.
Technical support: for technical questions related to this activity or issues with your CME certificate, please contact RedMedEd at (610) 251-6841 or firstname.lastname@example.org.
- Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser (PC): Google Chrome, Internet Explorer 9 or higher, or Firefox 26 or higher
- Internet browser (Mac): Google Chrome, Firefox 26 or higher, or Safari 5 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required
© 2017. This CME-certified program is held as copyrighted by the University of Cincinnati and RedMedEd. Through this notice, the University of Cincinnati and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.